300 related articles for article (PubMed ID: 34097256)
1. Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
Trivedi A; Oberoi RK; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Dutta S; Lee E
Clin Drug Investig; 2021 Jul; 41(7):647-652. PubMed ID: 34097256
[TBL] [Abstract][Full Text] [Related]
2. Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects.
Trivedi A; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Terminello B; Bhatia A; Dutta S; Lee E
Clin Drug Investig; 2021 Jul; 41(7):639-645. PubMed ID: 34110614
[TBL] [Abstract][Full Text] [Related]
3. Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator.
Trivedi A; Oberoi RK; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Simiens MA; Terminello B; Abbasi S; Dutta S; Lee E
Biopharm Drug Dispos; 2021 Jul; 42(7):319-328. PubMed ID: 34087948
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects.
Trivedi A; Malik FI; Mackowski M; Hutton S; Aoki M; Abbasi S; Dutta S; Lee E
Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):759-770. PubMed ID: 34415561
[TBL] [Abstract][Full Text] [Related]
5. No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.
Choi T; Komirenko AS; Riddle V; Kim A; Dhuria SV
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):818-826. PubMed ID: 30605260
[TBL] [Abstract][Full Text] [Related]
6. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects.
Trivedi A; Sohn W; Jafarinasabian P; Zhang H; Terminello B; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):129-133. PubMed ID: 34272833
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
[TBL] [Abstract][Full Text] [Related]
9. Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Trivedi A; Oberoi RK; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Hutton S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1442-1451. PubMed ID: 34107172
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
11. Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Trivedi A; Oberoi RK; Jafarinasabian P; Zhang H; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacokinet; 2021 Aug; 60(8):1041-1048. PubMed ID: 33768487
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.
Trivedi A; Sohn W; Hsu CP; Jafarinasabian P; Zhang H; Hutton S; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):388-396. PubMed ID: 34634185
[TBL] [Abstract][Full Text] [Related]
13. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.
Trivedi A; Malik FI; Jafarinasabian P; Zhang H; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):185-193. PubMed ID: 34145992
[TBL] [Abstract][Full Text] [Related]
15. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
16. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
17. Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects.
Vuu I; Wahlstrom J; Houk BE
Clin Pharmacokinet; 2023 Feb; 62(2):267-275. PubMed ID: 36529835
[TBL] [Abstract][Full Text] [Related]
18. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
19. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
Klamerus KJ; Alvey C; Li L; Feng B; Wang R; Kaplan I; Shi H; Dowty ME; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):499-507. PubMed ID: 27129125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
